Insight Molecular Diagnostics Inc's Business Segments

The company specializes in molecular diagnostic testing, primarily for transplanted organ rejection. It develops molecular diagnostic test kits that enable hospitals, transplant centers, and laboratories to perform in-house testing, as opposed to traditional send-out testing. This decentralized model also facilitates research to improve care standards and increase testing demand. The company’s intellectual property portfolio focuses on organ transplant, oncology therapy selection, and oncology therapy monitoring. Its product offerings include laboratory developed tests (LDTs), research use only (RUO) kits, and in vitro diagnostic (IVD) kitted clinical tests. The flagship product line, GraftAssure™, quantifies donor-derived cell-free DNA (dd-cfDNA) to monitor transplanted organ rejection. Products under this line include GraftAssureCore (LDT, CMS reimbursed), GraftAssureIQ (RUO kit), and GraftAssureDx (IVD kit in development). The company has a strategic partnership with Bio-Rad Laboratories, Inc. for digital PCR instruments and commercialization. It operates a CLIA-certified and CAP-accredited laboratory in Franklin, Tennessee, with research and development centers in Nashville, Tennessee, and Göttingen, Germany. The company is pursuing FDA and European Union regulatory approvals, having initiated a clinical trial in 2025 and submitted a marketing authorization application for GraftAssureDx in 2026. While it maintains a secondary focus on oncology assays, commercialization of these products is not planned within the next 12 months. Additionally, the company provides assay development and clinical testing services to life sciences and biotechnology companies. CMS reimbursement and coverage decisions by Medicare Administrative Contractors are important factors for its business operations.

iMDx is an early-stage diagnostics technology company engaged in the research, development, and commercialization of diagnostic tests. The company organizes its business based on products and services under a management approach overseen by the Chief Executive Officer and Chief Financial Officer. Its primary revenues are generated from Laboratory Services for life sciences customers, including biomarker discovery, assay design and development, clinical trial support, and biomarker tests, with additional revenue from Kitted Products. iMDx focuses on developing diagnostic tests related to organ transplant and oncology. The company's single reportable segment comprises Laboratory Services, Laboratory Developed Test Services, and Kitted Products. The Chief Operating Decision Maker evaluates segment performance and allocates resources using adjusted earnings or loss before interest, income taxes, depreciation, and amortization. Segment loss includes revenues, cost of revenues, research and development, and other operating expenses directly attributable to the segment, excluding depreciation, amortization, stock-based compensation, changes in fair value of contingent consideration, and impairments. Segment assets correspond to total assets reported in the consolidated balance sheets, and expenditures for long-lived assets are reflected in cash flows from investing activities.